Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway

Alia Shatanawi, Maritza J. Romero, Jennifer A. Iddings, Surabhi Chandra, Nagavedi S. Umapathy, Alexander D. Verin, Ruth B. Caldwell, R. William Caldwell

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by decreasing Larginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production. Elevated angiotensin II (ANG II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. We determined signaling mechanisms by which ANG II increases endothelial arginase function. Results show that ANG II (0.1 μM, 24 h) elevates arginase activity and arginase I expression in bovine aortic endothelial cells (BAECs) and decreases NO production. These effects are prevented by the arginase inhibitor BEC (100 μM). Blockade of ANG II AT1 receptors or transfection with small interfering RNA (siRNA) for Gα12 and Gα13 also prevents ANG II-induced elevation of arginase activity, but siRNA for Gαq does not. ANG II also elevates active RhoA levels and induces phosphorylation of p38 MAPK. Inhibitors of RhoA activation (simvastatin, 0.1 μM) or Rho kinase (ROCK) (Y- 27632, 10 μM; H1152, 0.5 μM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Furthermore, pretreatment of BAECs with p38 inhibitor SB-202190 (2 μM) or transfection with p38 MAPK siRNA prevents ANG II-induced increased arginase activity/expression and maintains NO production. Additionally, inhibitors of p38 MAPK (SB-203580, 5 μg·kg-1·day-1) or arginase (ABH, 8 mg·kg-1·day-1) or arginase gene knockout in mice prevents ANG II-induced vascular endothelial dysfunction and associated enhancement of arginase. These results indicate that ANG II increases endothelial arginase activity/expression through Gα12/13 G proteins coupled to AT1 receptors and subsequent activation of RhoA/ROCK/p38 MAPK pathways leading to endothelial dysfunction.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Cell Physiology
Volume300
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Arginase
rho-Associated Kinases
p38 Mitogen-Activated Protein Kinases
Angiotensin II
Blood Vessels
Small Interfering RNA
Nitric Oxide
Transfection
G12-G13 GTP-Binding Protein alpha Subunits
Endothelial Cells
Phosphorylation
Angiotensin Type 1 Receptor
Gene Knockout Techniques
Angiotensin Receptors
Simvastatin
Nitric Oxide Synthase Type III
Knockout Mice
Vasodilation
Endothelium

Keywords

  • Endothelial nitric oxide synthase dysfunction

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Cite this

Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. / Shatanawi, Alia; Romero, Maritza J.; Iddings, Jennifer A.; Chandra, Surabhi; Umapathy, Nagavedi S.; Verin, Alexander D.; Caldwell, Ruth B.; Caldwell, R. William.

In: American Journal of Physiology - Cell Physiology, Vol. 300, No. 5, 01.05.2011.

Research output: Contribution to journalArticle

Shatanawi, Alia ; Romero, Maritza J. ; Iddings, Jennifer A. ; Chandra, Surabhi ; Umapathy, Nagavedi S. ; Verin, Alexander D. ; Caldwell, Ruth B. ; Caldwell, R. William. / Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. In: American Journal of Physiology - Cell Physiology. 2011 ; Vol. 300, No. 5.
@article{6f2617850d3c4a02a4fb3ab4c04e4b1f,
title = "Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway",
abstract = "Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by decreasing Larginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production. Elevated angiotensin II (ANG II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. We determined signaling mechanisms by which ANG II increases endothelial arginase function. Results show that ANG II (0.1 μM, 24 h) elevates arginase activity and arginase I expression in bovine aortic endothelial cells (BAECs) and decreases NO production. These effects are prevented by the arginase inhibitor BEC (100 μM). Blockade of ANG II AT1 receptors or transfection with small interfering RNA (siRNA) for Gα12 and Gα13 also prevents ANG II-induced elevation of arginase activity, but siRNA for Gαq does not. ANG II also elevates active RhoA levels and induces phosphorylation of p38 MAPK. Inhibitors of RhoA activation (simvastatin, 0.1 μM) or Rho kinase (ROCK) (Y- 27632, 10 μM; H1152, 0.5 μM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Furthermore, pretreatment of BAECs with p38 inhibitor SB-202190 (2 μM) or transfection with p38 MAPK siRNA prevents ANG II-induced increased arginase activity/expression and maintains NO production. Additionally, inhibitors of p38 MAPK (SB-203580, 5 μg·kg-1·day-1) or arginase (ABH, 8 mg·kg-1·day-1) or arginase gene knockout in mice prevents ANG II-induced vascular endothelial dysfunction and associated enhancement of arginase. These results indicate that ANG II increases endothelial arginase activity/expression through Gα12/13 G proteins coupled to AT1 receptors and subsequent activation of RhoA/ROCK/p38 MAPK pathways leading to endothelial dysfunction.",
keywords = "Endothelial nitric oxide synthase dysfunction",
author = "Alia Shatanawi and Romero, {Maritza J.} and Iddings, {Jennifer A.} and Surabhi Chandra and Umapathy, {Nagavedi S.} and Verin, {Alexander D.} and Caldwell, {Ruth B.} and Caldwell, {R. William}",
year = "2011",
month = "5",
day = "1",
doi = "10.1152/ajpcell.00328.2010",
language = "English (US)",
volume = "300",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway

AU - Shatanawi, Alia

AU - Romero, Maritza J.

AU - Iddings, Jennifer A.

AU - Chandra, Surabhi

AU - Umapathy, Nagavedi S.

AU - Verin, Alexander D.

AU - Caldwell, Ruth B.

AU - Caldwell, R. William

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by decreasing Larginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production. Elevated angiotensin II (ANG II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. We determined signaling mechanisms by which ANG II increases endothelial arginase function. Results show that ANG II (0.1 μM, 24 h) elevates arginase activity and arginase I expression in bovine aortic endothelial cells (BAECs) and decreases NO production. These effects are prevented by the arginase inhibitor BEC (100 μM). Blockade of ANG II AT1 receptors or transfection with small interfering RNA (siRNA) for Gα12 and Gα13 also prevents ANG II-induced elevation of arginase activity, but siRNA for Gαq does not. ANG II also elevates active RhoA levels and induces phosphorylation of p38 MAPK. Inhibitors of RhoA activation (simvastatin, 0.1 μM) or Rho kinase (ROCK) (Y- 27632, 10 μM; H1152, 0.5 μM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Furthermore, pretreatment of BAECs with p38 inhibitor SB-202190 (2 μM) or transfection with p38 MAPK siRNA prevents ANG II-induced increased arginase activity/expression and maintains NO production. Additionally, inhibitors of p38 MAPK (SB-203580, 5 μg·kg-1·day-1) or arginase (ABH, 8 mg·kg-1·day-1) or arginase gene knockout in mice prevents ANG II-induced vascular endothelial dysfunction and associated enhancement of arginase. These results indicate that ANG II increases endothelial arginase activity/expression through Gα12/13 G proteins coupled to AT1 receptors and subsequent activation of RhoA/ROCK/p38 MAPK pathways leading to endothelial dysfunction.

AB - Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by decreasing Larginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production. Elevated angiotensin II (ANG II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. We determined signaling mechanisms by which ANG II increases endothelial arginase function. Results show that ANG II (0.1 μM, 24 h) elevates arginase activity and arginase I expression in bovine aortic endothelial cells (BAECs) and decreases NO production. These effects are prevented by the arginase inhibitor BEC (100 μM). Blockade of ANG II AT1 receptors or transfection with small interfering RNA (siRNA) for Gα12 and Gα13 also prevents ANG II-induced elevation of arginase activity, but siRNA for Gαq does not. ANG II also elevates active RhoA levels and induces phosphorylation of p38 MAPK. Inhibitors of RhoA activation (simvastatin, 0.1 μM) or Rho kinase (ROCK) (Y- 27632, 10 μM; H1152, 0.5 μM) block both ANG II-induced elevation of arginase activity and phosphorylation of p38 MAPK. Furthermore, pretreatment of BAECs with p38 inhibitor SB-202190 (2 μM) or transfection with p38 MAPK siRNA prevents ANG II-induced increased arginase activity/expression and maintains NO production. Additionally, inhibitors of p38 MAPK (SB-203580, 5 μg·kg-1·day-1) or arginase (ABH, 8 mg·kg-1·day-1) or arginase gene knockout in mice prevents ANG II-induced vascular endothelial dysfunction and associated enhancement of arginase. These results indicate that ANG II increases endothelial arginase activity/expression through Gα12/13 G proteins coupled to AT1 receptors and subsequent activation of RhoA/ROCK/p38 MAPK pathways leading to endothelial dysfunction.

KW - Endothelial nitric oxide synthase dysfunction

UR - http://www.scopus.com/inward/record.url?scp=79955565442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955565442&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00328.2010

DO - 10.1152/ajpcell.00328.2010

M3 - Article

VL - 300

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 5

ER -